Challenges and opportunities in achieving bioequivalence for fixed-dose combination products.
about
Rationale and clinical utility of the darunavir-cobicistat combination in the treatment of HIV/AIDSBioequivalence of saxagliptin/dapagliflozin fixed-dose combination tablets compared with coadministration of the individual tablets to healthy subjects.Challenges for the pharmaceutical technical development of protein coformulations.Pharmacokinetic and bioequivalence study of a telmisartan/S-amlodipine fixed-dose combination (CKD-828) formulation and coadministered telmisartan and S-amlodipine in healthy subjects.Patient-centered drug delivery and its potential applications for unmet medical needs.
P2860
Challenges and opportunities in achieving bioequivalence for fixed-dose combination products.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Challenges and opportunities i ...... xed-dose combination products.
@ast
Challenges and opportunities i ...... xed-dose combination products.
@en
type
label
Challenges and opportunities i ...... xed-dose combination products.
@ast
Challenges and opportunities i ...... xed-dose combination products.
@en
prefLabel
Challenges and opportunities i ...... xed-dose combination products.
@ast
Challenges and opportunities i ...... xed-dose combination products.
@en
P2860
P1433
P1476
Challenges and opportunities i ...... xed-dose combination products.
@en
P2093
Amitava Mitra
P2860
P2888
P304
P356
10.1208/S12248-012-9378-X
P407
P577
2012-06-09T00:00:00Z
P5875
P6179
1030171334